

Appl. No. 10/771,259

AMENDMENTS TO THE CLAIMS

1. Cancelled
2. (Currently Amended) A pharmaceutical composition for topical administration consisting essentially of a synergistic combination of a topically acceptable antiviral substance selected from the group consisting of acyclovir, cidofovir, desciclovir, famciclovir, ganciclovir, lobucavir, penciclovir, PMEA, valacyclovir, 2242, PAA, PFA and H2G or an ester, salt or solvate thereof and an anti-inflammatory glucocorticoid selected from the group consisting of alclometasone, amcinonide, beclomethasone, budesonide, ciclesonide, clobetasone, clocortolone, cloprednol, cortison, desonide, desoximethasone, dexamethasone, diflorosane, diflucortolone, difluprednate, fludrocortisone, fludroxycortid, flumethasone, flunisolide, fluocinolone acetonide, fluocinonide, fluocortin, fluocortolone, fluprednidene, fluticasone, halcinonide, halobetasol, halometasone, hydrocortisone, methylprednisolone, mometasone, paramethasone, prednisolone, prednicarbate, prednisone, prednylidene, rofleponide, tipredane and triamcinolone, and their esters, salts and solvates in a pharmaceutically acceptable carrier.
3. Cancelled
4. (Currently Amended) The pharmaceutical composition according to claim 2, wherein the anti-inflammatory glucocorticoid is selected from the group consisting of hydrocortisone, alclometasone, desonide, fluprednidene, flumethasone, hydrocortisone butyrate, clobetasone, triamcinolone acetonide, betamethasone, budesonide, desoximethasone, diflorosane, flucinolone, fluocortolone, fluticasone, methylprednisolone aceponate, mometasone and rofleponide or an ester, salt or solvate thereof.

Appl. No. 10/771,259

5. (Currently Amended) The pharmaceutical composition according to claim 12, wherein the anti-viral substance is foscarnet and the anti-inflammatory glucocorticoid is hydrocortisone, or an ester thereof.

6. (Currently Amended) The pharmaceutical composition according to claim 12, wherein the antiviral substance is foscarnet and the anti-inflammatory glucocorticoid is budesonide, or an ester thereof.

7. (Currently Amended) The pharmaceutical composition according to claim 12, wherein the antiviral substance is acyclovir, or an ester, salt or solvate thereof, and the anti-inflammatory glucocorticoid is hydrocortisone, or an ester thereof.

8. (Currently Amended) The pharmaceutical composition according to claim 5 comprising 0.1-10% (w/w) foscarnet and 0.005-3% (w/w) hydrocortisone.

9. (Currently Amended) The pharmaceutical composition according to claim 8 comprising 1-5% (w/w) foscarnet.

10. (Currently Amended) The pharmaceutical composition according to claim 8 comprising 0.3-3% (w/w) foscarnet and 0.25-1% (w/w) hydrocortisone.

11. (Currently Amended) The pharmaceutical composition according to claim 6 comprising 0.1-10% w/w foscarnet and 0.005-3% (w/w) budesonide.

12. (Currently Amended) The pharmaceutical composition according to claim 11 comprising 1-5% (w/w) foscarnet.

13. (Currently Amended) The pharmaceutical composition according to claim 7 comprising 0.1-10% (w/w) acyclovir and 0.005-3% (w/w) hydrocortisone.